Use of a recombinant murine cytomegalovirus expressing vesicular stomatitis virus G protein to pseudotype retroviral vectors

J Virol Methods. 1998 Jul;73(1):31-9. doi: 10.1016/s0166-0934(98)00034-2.

Abstract

A new method of producing vesicular stomatitis virus (VSV) G protein pseudotyped retroviral vectors is described. In this method, stocks of VSV-G pseudotyped vector were reproducibly obtained by infecting an env-, human, retroviral vector producer cell line with a recombinant murine cytomegalovirus (CMV) which expresses VSV-G protein. The recombinant murine CMV, RMCMVG, expressed VSV-G protein under transcriptional control of the human CMV immediate-early promoter. RMCMVG, like murine CMV, can infect human cells, but the infection is limited to the expression of the viral immediate-early genes; no productive replication of murine CMV occurs. Recombinant murine CMV vector infection of non-permissive cells may be useful in situations where high levels of gene expression are desired without concomitant viral vector replication.

MeSH terms

  • 3T3 Cells
  • Animals
  • Cell Line
  • Gene Transfer Techniques*
  • Genes, Viral / genetics
  • Genetic Therapy / methods
  • Genetic Vectors / genetics*
  • Giant Cells
  • Glycoproteins / biosynthesis
  • Glycoproteins / genetics
  • Humans
  • Membrane Glycoproteins*
  • Mice
  • Muromegalovirus / genetics*
  • Muromegalovirus / growth & development
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / genetics
  • Recombination, Genetic
  • Retroviridae / genetics*
  • Retroviridae / growth & development
  • Transfection
  • Vesicular stomatitis Indiana virus / genetics
  • Viral Envelope Proteins / biosynthesis*
  • Viral Envelope Proteins / genetics*
  • Viral Plaque Assay

Substances

  • G protein, vesicular stomatitis virus
  • Glycoproteins
  • Membrane Glycoproteins
  • Recombinant Proteins
  • Viral Envelope Proteins